Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Opens in a new tab or window SARS-CoV-2 infection was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022-2023 respiratory illness ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

And, of course, wearing a mask won't hurt. Respiratory viruses that cause the common cold, respiratory syncytial virus (RSV), COVID-19 and flu peak at this time of year. Vaccines can help head off ...

Roberts said the main hospital has about 1,500 beds and about 150 patients, or 10%, are admitted with COVID, flu and RSV. MORE: CDC warns of 'high' respiratory virus activity as cases increase ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...